Chai Discovery’s $400m raise triples its value to $3.8bn in seven months. It is the latest sign that AI drug discovery has moved from promise to deployment.
AI drug discovery just minted another fast-rising star. Chai Discovery has raised a $400m Series C that values the San Francisco startup at $3.8bn, the company said. That is nearly triple the $1.3bn it was worth seven months ago.
Index Ventures led the round. Kleiner Perkins, Sequoia Capital, and Dimension joined, alongside new backers including Bain Capital Ventures, Battery Ventures, and Baillie Gifford. Returning investors OpenAI and Thrive Capital also put in more money.
The raise takes Chai’s total funding above $600m in about eleven months. It closed a $70m Series A in mid-2025, then a $130m round at a $1.3bn valuation in December.
What Chai builds
